Cécile is a master student in Computational Science at EPFL (Switzerland). She joined the Huber group for an internship in August 2017 and will work with Dorothee and Arne on proteomics data to study drug (off-)targets and systems-wide effects of drug treatment.
Frederik has a PhD in Applied Mathematics from Heidelberg University and the German Cancer Research Center (DKFZ). He works on developing statistical methods for high-dimensional heterogeneous data and the analysis of multi-omic level drug treatment effects in collaboration with Cellzome.
Almut is a master student in molecular biotechnology at the University of Heidelberg. She joined the Huber group in 2017 and works on the analysis of RNA-seq data from Chronic lymphatic leukemia (CLL) samples.
Jennifer has a PhD in Biology from the University Heidelberg. She joined EMBL in January 2017 and is working on the SOUND project. Her main tasks are the management of data resources and data analysis workflows related to the SMART project “Drug perturbation profiling of primary blood cancers” which encompasses researchers and activities at EMBL, NCT Heidelberg, DKFZ and Heidelberg University Hospital.
Arne has a PhD degree from the Radboud University (Nijmegen, The Netherlands). His previous research in the laboratory of Prof. Michiel Vermeulen focused on the identification and quantification of protein-protein and DNA-protein interactions using quantitative proteomics. As a EIPOD postdoctoral fellow at EMBL, he is studying the systems-wide effects of drug treatment in collaboration with Cellzome and the Steinmetz group.
At EMBL, Nikos works on data-driven hypothesis weighting for false discovery rate control as part of his Bachelor’s and Master’s thesis, which he will finish in August 2016. In September, he will join Stanford’s Statistics department to start his PhD!
Sophie studied Molecular Biotechnology at the University of Heidelberg. She joined the Huber Group in Spring 2014 as student research assistant and worked on genomic biomarkers of drug sensitivity in primary blood cancer cells. For her PhD thesis, Sophie is now joining the group of Sascha Dietrich at NCT Heidelberg, where she will work on the SYMPATHY project, an integrated system medicine approach to personalized and targeted therapy in leukaemia and lymphoma. This multidisciplinary project is intended to have direct clinical impact on patient care in blood cancers.
At EMBL, Jackie worked on her Master thesis, which she successfully finished in October 2015 with an excellent mark! In September 2016, she will start to work on her PhD thesis at the Centre for Genomic Regulation in Barcelona. Jackie was awarded the La Caixa Fellowship for the coming four years.
Karsten Bach has a B.Sc. in Biology from the University of Bonn. He joined the Huber group in March 2016. At EMBL, he is finishing up his M.Sc. in Molecular Biotechnology and working on quantitative proteomics together with Dorothee Childs and Nikos Ignatiadis.
Dorothee Childs presented her work at the EMBL-Wellcome Genome Campus Conference “Target Validation using Genomics and Informatics 2015″, which took place from 8th to 10th December 2015 in Cambridge.
More than 200 people attended this ground-breaking conference. Dorothee gave a talk on “Screening for drug targets in intact cells by thermal proteome profiling”, a project in which she is involved as part of a collaboration between EMBL Heidelberg and GSK’s SME Cellzome, which is also based in Heidelberg.”